Tetrazepam

Summary

Tetrazepam (CHEMBL2105527) is an approved small molecule (ATC M03BX07).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M03BX07
• Chemistry: 288.77 Da · C16H17ClN2O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105527
Name	Tetrazepam
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	25215
ATC	M03BX07
Molecular formula	C16H17ClN2O
Molecular weight	288.77
InChIKey	IQWYAQCHYZHJOS-UHFFFAOYSA-N

SMILES: CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CCCCC3

IUPAC name: 7-chloro-5-(cyclohexen-1-yl)-1-methyl-3H-1,4-benzodiazepin-2-one

Also known as: CB 4261, CB-4261, Myolastan, Tetrazepam, TETRAZEPAM

Patent coverage: 521 distinct patent families (2,082 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,060 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).